Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases.
For the year ended December 31, 2025, Arbutus reported total revenue of $14.1 million. Additionally, the company recorded a net loss of $0.17 per basic and diluted common share.
Arbutus ended 2025 with $91.5 million in cash, cash equivalents, and marketable securities. Furthermore, a global settlement with Moderna will yield a $950 million upfront payment to Arbutus and Genevant in July 2026, with Arbutus entitled to 20% after litigation costs.